BioXcel Therapeutics (FRA:BX2) Accumulated Depreciation : €-1.17 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

BioXcel Therapeutics's quarterly accumulated depreciation increased from Sep. 2023 (€-1.05 Mil) to Dec. 2023 (€-1.09 Mil) and increased from Dec. 2023 (€-1.09 Mil) to Mar. 2024 (€-1.17 Mil).

BioXcel Therapeutics's annual accumulated depreciation increased from Dec. 2021 (€-0.53 Mil) to Dec. 2022 (€-0.84 Mil) and increased from Dec. 2022 (€-0.84 Mil) to Dec. 2023 (€-1.09 Mil).

BioXcel Therapeutics Accumulated Depreciation Historical Data

The historical data trend for BioXcel Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Accumulated Depreciation Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-0.16

-0.30

-0.53

-0.84

-1.09

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-0.90	-0.96	-1.05	-1.09	-1.17

BioXcel Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

BioXcel Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines